BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19726199)

  • 1. Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives.
    Yan J; Sun L; Wu G; Yi P; Yang F; Zhou L; Zhang X; Li Z; Yang X; Luo H; Qiu M
    Bioorg Med Chem; 2009 Oct; 17(19):6937-41. PubMed ID: 19726199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
    Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
    J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors.
    Sheng R; Lin X; Zhang J; Chol KS; Huang W; Yang B; He Q; Hu Y
    Bioorg Med Chem; 2009 Sep; 17(18):6692-8. PubMed ID: 19692250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B.
    He XC; Feng S; Wang ZF; Shi Y; Zheng S; Xia Y; Jiang H; Tang XC; Bai D
    Bioorg Med Chem; 2007 Feb; 15(3):1394-408. PubMed ID: 17126020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
    Pan L; Tan JH; Hou JQ; Huang SL; Gu LQ; Huang ZS
    Bioorg Med Chem Lett; 2008 Jul; 18(13):3790-3. PubMed ID: 18524585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of coumarin derivatives tethered to an edrophonium-like fragment as highly potent and selective dual binding site acetylcholinesterase inhibitors.
    Pisani L; Catto M; Giangreco I; Leonetti F; Nicolotti O; Stefanachi A; Cellamare S; Carotti A
    ChemMedChem; 2010 Sep; 5(9):1616-30. PubMed ID: 20677317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.
    Huang L; Luo Z; He F; Lu J; Li X
    Bioorg Med Chem; 2010 Jun; 18(12):4475-84. PubMed ID: 20471843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites.
    Gemma S; Gabellieri E; Huleatt P; Fattorusso C; Borriello M; Catalanotti B; Butini S; De Angelis M; Novellino E; Nacci V; Belinskaya T; Saxena A; Campiani G
    J Med Chem; 2006 Jun; 49(11):3421-5. PubMed ID: 16722663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and evaluation of carbamate-modified (-)-N(1)-phenethylnorphysostigmine derivatives as selective butyrylcholinesterase inhibitors.
    Takahashi J; Hijikuro I; Kihara T; Murugesh MG; Fuse S; Tsumura Y; Akaike A; Niidome T; Takahashi T; Sugimoto H
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1721-3. PubMed ID: 20137941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
    Huang L; Shi A; He F; Li X
    Bioorg Med Chem; 2010 Feb; 18(3):1244-51. PubMed ID: 20056426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors.
    Jia P; Sheng R; Zhang J; Fang L; He Q; Yang B; Hu Y
    Eur J Med Chem; 2009 Feb; 44(2):772-84. PubMed ID: 18550228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors.
    Sheng R; Lin X; Li J; Jiang Y; Shang Z; Hu Y
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3834-7. PubMed ID: 15993600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors.
    Hu Y; Zhang J; Chandrashankra O; Ip FC; Ip NY
    Bioorg Med Chem; 2013 Feb; 21(3):676-83. PubMed ID: 23273608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, evaluation and QSAR analysis of N(1)-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors.
    Takahashi J; Hijikuro I; Kihara T; Murugesh MG; Fuse S; Kunimoto R; Tsumura Y; Akaike A; Niidome T; Okuno Y; Takahashi T; Sugimoto H
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1718-20. PubMed ID: 20137934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of novel 4-[(3H,3aH,6aH)-3-phenyl)-4,6-dioxo-2-phenyldihydro-2H-pyrrolo[3,4-d]isoxazol-5(3H,6H,6aH)-yl]benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents.
    Anand P; Singh B
    Bioorg Med Chem; 2012 Jan; 20(1):521-30. PubMed ID: 22172310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel N-benzylpyridinium moiety linked to arylisoxazole derivatives as selective butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study.
    Vafadarnejad F; Karimpour-Razkenari E; Sameem B; Saeedi M; Firuzi O; Edraki N; Mahdavi M; Akbarzadeh T
    Bioorg Chem; 2019 Nov; 92():103192. PubMed ID: 31446239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
    Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
    J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of novel 2-(aminoalkyl)-isoindoline-1,3-dione derivatives as dual-binding site acetylcholinesterase inhibitors.
    Ignasik M; Bajda M; Guzior N; Prinz M; Holzgrabe U; Malawska B
    Arch Pharm (Weinheim); 2012 Jul; 345(7):509-16. PubMed ID: 22467516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.